Focused On-demand Library for Rho guanine nucleotide exchange factor 18

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We use our state-of-the-art dedicated workflow for designing focused libraries.

 Fig. 1. The sreening workflow of Receptor.AI

Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.

Our library distinguishes itself through several key aspects:

  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.
  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.
  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.
  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.







Alternative names:

114 kDa Rho-specific guanine nucleotide exchange factor; Septin-associated RhoGEF

Alternative UPACC:

Q6ZSZ5; A8MV62; B5ME81; I3L1I5; O60274; Q6DD92


Rho guanine nucleotide exchange factor 18, also known as a 114 kDa Rho-specific guanine nucleotide exchange factor or Septin-associated RhoGEF, plays a pivotal role in cellular processes. It acts as a guanine nucleotide exchange factor for RhoA GTPases, promoting actin stress fiber formation, and for RAC1, enhancing reactive oxygen species production. This protein does not influence CDC42 but is activated by G protein beta-gamma subunits, integrating effects of LPA and other GPCR agonists on cell morphology and ROS generation.

Therapeutic significance:

Rho guanine nucleotide exchange factor 18 is implicated in Retinitis pigmentosa 78, a retinal dystrophy characterized by night vision blindness and progressive loss of visual field. Understanding the role of this protein could open doors to potential therapeutic strategies for this autosomal recessive disease.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
No Spam. Cancel Anytime.